Advice
following a resubmission:
argatroban (Exembol®) is accepted for use within NHS Scotland.
Indication under review: anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy.
Argatroban produces anticoagulant effects in adults with heparin-induced thrombocytopenia type II. However there is limited evidence that the anticoagulant effects are associated with a reduction in thrombosis and deaths due to thrombosis.
Download detailed advice137KB (PDF)
Medicine details
- Medicine name:
- argatroban, 100mg/ml, concentrate for solution for infusion (Exembol®)
- SMC ID:
- 812/12
- Indication:
- For anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy.
- Pharmaceutical company
- Mitsubishi Pharma Europe Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 12 August 2013